arrow
J

Joseph Maakaron

marrow transplant group of georgia
H指数:19
被引数:1,522

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma

静脉注射硼替佐米、白蛋白结合型紫杉醇和地塞米松(VAD)方案治疗复发/难治性多发性骨髓瘤的I期临床试验

2026-03-270
PRE
Phase 1/2 study of donor-derived anti-CD33 CAR T cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT

供体来源的anti-CD33 CAR T细胞疗法 (VCAR33) 治疗异基因HCT后复发/难治性AML的1/2期研究

Blood
IF23.1
2026-02-060
PRE
Frailty is associated with low physical activity and poor sleep quality in patients undergoing myeloablative allogeneic hematopoietic cell transplantation: a Fitbit® pilot study

虚弱与接受骨髓清除性异基因造血细胞移植患者的低身体活动量和睡眠质量差相关:一项Fitbit®初步研究

2025-12-080
OAAI
Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

评估商业用Axicabtagene Ciloleucel(axi-cel)和Tisagenlecleucel(tisa-cel)治疗复发或难治性(R/R)滤泡性淋巴瘤(FL)的结局和毒性的研究:来自10家美国学术中心的真实世界证据(RWE)

BLOOD
IF23.1
2024-11-050
PRE
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma
2024-10-100
OAAI
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis
LEUKEMIA
IF13.4
2024-05-150
PRE
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

确定最佳氟达拉滨暴露以改善axi-cel治疗侵袭性b细胞非霍奇金淋巴瘤后的结果

2023-09-1812
OAAI
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
2023-09-015
PRE
Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease
2023-08-017
OAAI
Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma
2023-07-1915
PRE
Postibrutinib relapse outcomes for patients with marginal zone lymphoma
2023-01-101
OAAI